2023 World Conference on Lung Cancer (Posters)-EP09.04. Survival of Non-small Cell Lung Cancer with and without Brain Metastasis - Shifting to a Merging Survival Curves Era

EP09.04. Survival of Non-small Cell Lung Cancer with and without Brain Metastasis - Shifting to a Merging Survival Curves Era - PDF(Slides)

Back to course

Pdf Summary

This study examines the survival rates of patients with non-small cell lung cancer (NSCLC) with and without brain metastasis (BM). Historically, NSCLC patients with BM were excluded from clinical trials due to poor prognosis. However, advances in therapy have improved survival rates for these patients. The study analyzed data from 429 stage IV NSCLC patients, including 134 with BM and 225 without BM. Of these patients, 80 had BM at the time of diagnosis and 54 developed BM after diagnosis. The study found that the overall survival of NSCLC patients with BM was not inferior to those without BM. This challenges the previous assumption of a worse prognosis for patients with neurological symptoms. The study suggests including NSCLC patients with BM in clinical trials, as many studies now allow patients with treated, controlled, asymptomatic BM to participate. However, there is a rise in trials that still exclude patients with symptomatic, untreated, or uncontrolled BM. The data shows that the survival curves for patients with and without BM are merging, indicating a similar prognosis. Overall, this study highlights the need to reconsider the exclusion of NSCLC patients with BM from clinical trials and suggests that they should be included based on their improved survival outcomes.

Asset Subtitle

Itamar Averbuch

Meta Tag

Speaker Itamar Averbuch

Topic Metastatic NSCLC: Local Therapies - Predictive & Prognostic Biomarkers

Keywords

non-small cell lung cancer

NSCLC

brain metastasis

survival rates

clinical trials

prognosis

therapy

neurological symptoms

asymptomatic BM

exclusion from trials